Tango Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Tango Therapeutics, Inc. (TNGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 1.66 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-11
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 835.92K shares, a 120.65% increase year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 828.94K shares, a 207.12% increase year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 1.03M shares, a 139.82% increase year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 641.22K shares, a 8.55% decline year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 2.32M shares, a 40.60% increase from fiscal 2024.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 1.65M shares, a 47.65% increase from fiscal 2023.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.12M shares, a 6.56% increase from fiscal 2022.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 1.05M shares, a 269.80% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 835.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 1.66M shares 10-Q · filed 2026-08-11 | 2.70M shares derived: sum of 3 quarters · filed 2026-08-11 | 3.34M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 828.94K shares 10-Q · filed 2026-05-13 | 1.86M shares derived: sum of 2 quarters · filed 2026-05-13 | 2.50M shares derived: sum of 3 quarters · filed 2026-05-13 | 2.88M shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 1.03M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 1.67M shares derived: sum of 2 quarters · filed 2026-03-05 | 2.05M shares derived: sum of 3 quarters · filed 2026-03-05 | 2.32M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 641.22K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 1.02M shares derived: sum of 2 quarters · filed 2025-11-04 | 1.29M shares 10-Q · filed 2025-11-04 | 1.72M shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 378.84K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 648.75K shares 10-Q · filed 2025-08-05 | 1.08M shares derived: sum of 3 quarters · filed 2025-08-05 | 1.78M shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 269.91K shares 10-Q · filed 2025-05-12 | 699.52K shares derived: sum of 2 quarters · filed 2025-05-12 | 1.40M shares derived: sum of 3 quarters · filed 2025-05-12 | 1.82M shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 429.61K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 1.13M shares derived: sum of 2 quarters · filed 2025-02-27 | 1.55M shares derived: sum of 3 quarters · filed 2025-02-27 | 1.65M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 701.15K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 1.12M shares derived: sum of 2 quarters · filed 2024-11-06 | 1.22M shares 10-Q · filed 2024-11-06 | 1.64M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 418.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 519.51K shares 10-Q · filed 2024-08-07 | 941.63K shares derived: sum of 3 quarters · filed 2024-08-07 | 1.06M shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 100.86K shares 10-Q · filed 2024-05-08 | 522.98K shares derived: sum of 2 quarters · filed 2024-05-08 | 641.38K shares derived: sum of 3 quarters · filed 2024-05-08 | 1.09M shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 422.12K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | 540.52K shares derived: sum of 2 quarters · filed 2024-03-18 | 984.50K shares derived: sum of 3 quarters · filed 2024-03-18 | 1.12M shares 10-K · filed 2024-03-18 |
| 2023-09-30 | 118.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 562.38K shares derived: sum of 2 quarters · filed 2023-11-08 | 695.59K shares 10-Q · filed 2023-11-08 | 986.29K shares derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | 443.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 577.18K shares 10-Q · filed 2023-08-07 | 867.89K shares derived: sum of 3 quarters · filed 2023-08-07 | 912.33K shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 133.21K shares 10-Q · filed 2023-05-09 | 423.92K shares derived: sum of 2 quarters · filed 2023-05-09 | 468.36K shares derived: sum of 3 quarters · filed 2023-05-09 | 1.16M shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 290.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | 335.15K shares derived: sum of 2 quarters · filed 2023-03-27 | 1.03M shares derived: sum of 3 quarters · filed 2023-03-27 | 1.05M shares 10-K · filed 2023-03-27 |
| 2022-09-30 | 44.44K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 738.78K shares derived: sum of 2 quarters · filed 2022-11-10 | 758.19K shares 10-Q · filed 2022-11-10 | 794.40K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 694.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 713.75K shares 10-Q · filed 2022-08-10 | 749.96K shares derived: sum of 3 quarters · filed 2022-08-10 | |
| 2022-03-31 | 19.41K shares 10-Q · filed 2022-05-11 | 55.62K shares derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2021-12-31 | 36.21K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 283.64K shares 10-K · filed 2022-03-28 | ||
| 2021-09-30 | 247.43K shares 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |